Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research

Table 1

This table summarizes the hemostatic drugs, details of clinical trials completed in AIS, route (i.v.: intravenous), phases, number of patients enrolled, and clinical trial number.

Summary of antithrombotic drug trials
Drug	Dose	Time window	Phase	Number of patients	Clinical trial number	Citation
Eptifibatide (CLEAR)	r-tPA (0.3 mg/kg versus 0.45 mg/kg) + eptifibatide (75 μg/kg bolus followed by 0.75 μg/kg/min infusion for 2 hours) or r-tPA (0.9 mg/kg)	3 hours	1/2	10	NCT00250991	[3]
Eptifibatide (CLEAR-ER)	0.6 mg/kg r-tPA + eptifibatide (135 μg/kg bolus and a 2-hour infusion at 0.75 μg/kg per minute) versus r-tPA (0.9 mg/kg)	3 hours	2	126	NCT00894803	[5]
Eptifibatide (CLEAR-FDR)	i.v. bolus of 135 μg/kg eptifibatide followed by an i.v. infusion of 0.75 μg/kg/min eptifibatide for 2 hours	3 hours	2	27	NCT01977456	[6]
Revacept	Single i.v. of 10, 20, 40, 80, or 160 mg	Laboratory, clinical exams	1	30	NCT01042964	[7]